72351-36-1

Basic information

• Product Name: 1-(DIPHENYLMETHYL)-3-(HYDROXYMETHYL)AZETIDINE
• Synonyms: BUTTPARK 37\04-19;1-(DIPHENYLMETHYL)-3-(HYDROXYMETHYL)AZETIDINE;(1-BENZHYDRYLAZETIDIN-3-YL)METHANOL;1-Diphenylmethyl-3-(hydro...;1-(diphenylMethyl)-3-(hydroxyMethyl)azetidine-hcl;[1-(Diphenylmethyl)azetidin-3-yl]methanol;1-Benzhydryl-3-(hydroxymethyl)azetidine;(1-Benzhydrylazetidin-3-yl)
• CAS NO: 72351-36-1
• Molecular Formula: C₁₇H₁₉NO
• Molecular Weight: 253.34
• Mol File: 72351-36-1.mol

Chemical Properties

• Melting Point: 113-115°C
• Boiling Point: 334.5 °C at 760 mmHg
• Flash Point: 139.5 °C
• Appearance: /
• Density: 1.137
• Vapor Pressure: 5.03E-05mmHg at 25°C
• Refractive Index: 1.609
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-(DIPHENYLMETHYL)-3-(HYDROXYMETHYL)AZETIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(DIPHENYLMETHYL)-3-(HYDROXYMETHYL)AZETIDINE(72351-36-1)
• EPA Substance Registry System: 1-(DIPHENYLMETHYL)-3-(HYDROXYMETHYL)AZETIDINE(72351-36-1)

Safety Data

• Hazardous Substances Data: 72351-36-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1-(DIPHENYLMETHYL)-3-(HYDROXYMETHYL)AZETIDINE is used as a building block in organic synthesis for its ability to participate in various chemical reactions, enabling the design and synthesis of new molecules with specific properties and functions.
Used in Medicinal Chemistry:
1-(DIPHENYLMETHYL)-3-(HYDROXYMETHYL)AZETIDINE is used as a key intermediate in the development of pharmaceutical compounds, leveraging its unique structure and chemical properties to create molecules with potential therapeutic effects.
Used in Drug Discovery:
1-(DIPHENYLMETHYL)-3-(HYDROXYMETHYL)AZETIDINE is used as a starting material in drug discovery for exploring its potential biological activities and pharmacological properties, with the aim of identifying new therapeutic agents.
Used in Chemical Research:
1-(DIPHENYLMETHYL)-3-(HYDROXYMETHYL)AZETIDINE is used as a subject of study in chemical research to better understand its properties, reactivity, and potential applications in various fields, including materials science and nanotechnology.

InChI:InChI=1/C17H19NO/c19-13-14-11-18(12-14)17(15-7-3-1-4-8-15)16-9-5-2-6-10-16/h1-10,14,17,19H,11-13H2

Upstream product

• 91-00-9 Benzhydrylamine 
• 36476-86-5 1-(1,1-diphenylmethyl)azetidine-3-carbonitrile 
• 33301-41-6 1-benzhydryl-3-azetidinyl methanesulfonate 
• 18621-17-5 1-(diphenylmethyl)-3-hydroxyazetidine 
• 53871-06-0 1-(diphenylmethyl)-3-methoxycarbonylazetidine 
• 36476-87-6 1-benzhydrylazetidine-3-carboxylic acid 

Downstream Products

• 142253-56-3 3-hydroxymethyl-azetidine-1-carboxylic acid tert-butyl ester 
• 95849-02-8 3-hydroxymethyl-1-azetidine 
• 321890-21-5 [1-(1,1-diphenylmethyl)azetidin-3-ylmethyl]dimethylamine 
• 1266244-56-7 C₂₄H₂₁ClF₃NO 
• 955400-19-8 1-benzhydryl-3-methoxymethylazetidine 
• 162698-41-1 (1-benzhydrylazetidin-3-yl)methyl methanesulfonate 
• 928038-44-2 3-(hydroxymethyl)azetidine hydrochloride 

Relevant articles and documents

Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders

To try and generate broad spectrum human rhinovirus VP1 inhibitors with more attractive physicochemical, DMPK and safety profiles, we explored the current SAR of known VP1 compounds. This lead to the identification of specific structural regions where reduction in polarity can be achieved, so guiding chemistry to analogues with significantly superior profiles to previously reported inhibitors.

AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

Disclosed is a compound having a strong affinity to serotonin-4 receptors, which is useful as an enterokinesis-promoting agent or a digestive tract function-improving agent. Specifically, disclosed is a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. Also specifically disclosed is a pharmaceutical composition containing a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. [In Formula (1), Ar represents a group represented by Formula (Ar-1) or Formula (Ar-2).]

PYRIDINE OR PYRIMIDINE DERIVATIVE HAVING EXCELLENT CELL GROWTH INHIBITION EFFECT AND EXCELLENT ANTI-TUMOR EFFECT ON CELL STRAIN HAVING AMPLIFICATION OF HGFR GENE

A pyridine or pyrimidine derivative represented by the formula (I) has an excellent HGFR inhibitory activity and exhibits strong cell proliferation inhibitory effect and anti-tumor effect against cancer cell lines with amplified HGFR gene. wherein R1 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R2 and R3 represent hydrogen; R4, R5, R6, and R7 may be the same or different and each represents hydrogen, halogen, C1-6 alkyl or the like; R8 represents hydrogen or the like; R9 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; n represents an integer of 1 or 2; X represents -CH=, nitrogen.

PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS

The invention relates to 2-phenyl-pyrimidine derivatives containing a phosphonic acid motif and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals. (I).

NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3)

A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity. [R1 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R2 and R3 represent hydrogen; R4, R5, R6, and R7 may be the same or different and each represents hydrogen, halogen, C1-6 alkyl or the like; R8 represents hydrogen or the like; R9 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; n represents an integer of 1 or 2; X represents -CH=, nitrogen or the like.]

VLA-4 INHIBITORY DRUG

There is provided a VLA-4 inhibitory drug having good oral absorbability and exhibiting sufficient anti-inflammatory effects when administered orally. A compound represented by the following formula (I): wherein R1 represents a hydrogen atom or a C1-8 alkyl group; R2 represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group, orabenzyloxygroupwhichmaybe substituted; Q represents a monocyclic or bicyclic nitrogen-containing heterocyclic group which may be substituted, and has a nitrogen atom as the bonding site; Y represents an oxygen atom or CH2; W represents a bicyclic aromatic hydrocarbon ring group which may be substituted, or a bicyclic aromatic heterocyclic group whichmaybe substituted; R3a, R3b and R3c each independently represent a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group; and A1 represents a nitrogen atom or C-R3d (wherein R3d represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group), or a salt thereof, or a VLA-4 inhibitory drug comprising the compound or the salt as an active ingredient.

Process for preparing phenoxypyridine derivatives

A process for preparing a compound represented by the formula (I): comprising reacting a compound represented by the formula (II) or salt thereof: with a compound represented by the formula (III): in the presence of a condensation reagent, wherein R1 represents 1) optionally substituted azetidin-1-yl, 2) optionally substituted pyrrolidin-1-yl, 3) optionally substituted piperidin-1-yl, etc.; R2, R3, R4 and R5 may be the same or different and each represents hydrogen or fluorine; and R6 represents hydrogen or fluorine.

AZETIDINE-SUBSTITUTED PYRAZOLINES AS PAR-1 ANTAGONISTS

The invention relates to blood clotting, and especially to the use of azetidine-substituted pyrazolines as medicaments, novel azetidine-substituted pyrazolines, methods for the production thereof, and the use of the same for producing medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular diseases, preferably thromboembolic diseases.

Novel 5-HT2A receptor ligands

Compounds of formula I: are antagonists of the human 5-HT2A receptor, and hence useful in treatment or prevention of a variety of neurological conditions.

Aryloxy and aryloxyalklazetidines as antiarrhythmic and anticonvulsant agents

Methods of treating cardiac arrhythmias and convulsions in warm-blooded animas and pharmaceutical compositions therefor are disclosed. The compounds useful in the methods of treatment and compositions are represented by the formula STR1 where n is 0 to 3 and R is H, C1 -C4 alkyl or arylalkyl and Ar is phenyl or substituted phenyl.